Introduction {#sec1-0300060517729589}
============

Axillary management in breast cancer has evolved from routine axillary lymph node dissection (ALND) to sentinel lymph node (SLN) biopsy. The SLN is the first lymph node to receive lymphatic drainage from a tumor and theoretically the first site of lymphatic metastasis. In the 1990s, SLN biopsy (SLNB) was developed as a surgical technique for the local axillary lymph nodes in patients with breast cancer.^[@bibr1-0300060517729589]^ This technique was a landmark in the development of breast surgery and has become an important part of the standard treatment of early breast cancer.

Large-scale clinical trials have confirmed that SLNB and ALND show no significant differences in disease-free survival, overall survival, or recurrence-free survival in SLN-negative patients,^[@bibr2-0300060517729589][@bibr3-0300060517729589]--[@bibr4-0300060517729589]^ and SLNB can accurately predict axillary lymph node metastasis. Many nomograms have also been developed to predict the risk of non-SLN metastasis to avoid unnecessary ALND. The findings of the Z0011 trial changed the standard surgical paradigm in breast cancer by showing that patients with breast cancer with one to two positive SLNs who are treated with conservative breast surgery may avoid ALND.^[@bibr5-0300060517729589]^ The number of negative SLNs has been identified as an independent predictor of non-SLN metastasis,^[@bibr6-0300060517729589]^ and the presence of negative SLNs may reduce the risk of residual disease in non-SLNs. In principle, SLN-negative patients can avoid ALND; however, the procedure by which the SLN itself is obtained may lead to unnecessary injury. Hence, it is important to clarify whether the identification of more SLNs is beneficial. Accordingly, the objective of this study was to determine how many SLNs are needed to predict non-SLN metastasis in patients with breast cancer.

Methods {#sec2-0300060517729589}
=======

Patients {#sec3-0300060517729589}
--------

Patients with stage cT1-2 N0 breast cancer who underwent SLNB from January 2013 to July 2015 in the Department of Breast, Women's Hospital, School of Medicine, Zhejiang University, China were included in the present study. None of the enrolled patients had undergone previous systemic treatment.

Surgical procedure and pathological evaluation {#sec4-0300060517729589}
----------------------------------------------

Lymphatic mapping for SLNB was performed using blue dye. Blue dye was injected into the subareolar and peritumoral regions of each patient 5 minutes before SLNB. During the operation, we generally observed the blue-stained lymphatics on the lateral border of the pectoralis major muscle through the blue-stained lymph tube. We then separated the blue-stained lymph nodes as the SLNs.

Intraoperative frozen section analyses were routinely performed for every harvested SLN. Patients with negative SLNs underwent ALND or no further axillary treatment. ALND was avoided in patients with positive SLNs if they met the Z0011 criteria; otherwise, level I or II ALND was performed.

Informed consent was obtained from all patients, and all procedures performed were in accordance with the ethical standards of the responsible committee on human experimentation in the Women's Hospital, School of Medicine, Zhejiang University. Immunohistochemical staining was routinely performed to obtain a preoperative diagnosis of SLN metastasis. The SLN metastasis was classified as macrometastasis (MAC), micrometastasis, or isolated tumor cells according to the American Joint Committee on Cancer 7th Edition.^[@bibr7-0300060517729589]^ In addition, every node was postoperatively examined using hematoxylin and eosin staining of serial sections.

Adjuvant therapy {#sec5-0300060517729589}
----------------

All patients were treated according to the National Comprehensive Cancer Network guidelines. Radiotherapy was performed for patients who underwent conservative breast surgery and patients with positive lymph nodes. Chemotherapy regimens were based on anthracyclines and taxanes, and hormone therapy was based on tamoxifen and aromatase inhibitors. From 2005, adjuvant trastuzumab therapy was used for HER-2-positive patients.

Evaluation {#sec6-0300060517729589}
----------

All tumors were invasive carcinoma of no special type according to the World Health Organization Classification of Breast Tumors, 4th Edition.^[@bibr8-0300060517729589]^

In the evaluation of estrogen or progesterone receptor positivity, a 10% positive rate for each parameter was considered positive. For HER-2, diffusely stained tumors (triple-positive) or tumors with positive fluorescent in situ hybridization results (double-positive tumors) were considered positive. A Ki67 index of \<14% was considered negative.

Follow-up {#sec7-0300060517729589}
---------

Patients who did not undergo ALND were followed up. All patients were clinically examined every 3 months in the first year postoperatively, then every 6 months thereafter. Examinations involved assessment of the breasts or chest wall, axillae, and supraclavicular fossae. An annual mammogram was performed. Dedicated breast ultrasound was also performed if necessary. Other hematological and imaging examination were performed according to the clinical situation.

Statistical analysis {#sec8-0300060517729589}
--------------------

The association between clinicopathological features and non-SLN metastasis was evaluated using univariate and multivariate analysis. Categorical variables in the univariate analysis were compared using the two-tailed Fisher's exact test or the chi-square test. Multivariate analysis was performed using logistic regression analysis. All data were analyzed using SAS 9.3 statistical software (SAS Institute Inc., Cary, NC, USA). A P value of \<0.05 was considered statistically significant.

Results {#sec9-0300060517729589}
=======

Patients who underwent ALND {#sec10-0300060517729589}
---------------------------

In total, 723 patients with stage cT1-2 N0 breast cancer underwent SLNB. The characteristics of the patients who underwent ALND (*n* = 472) are provided in [Table 1](#table1-0300060517729589){ref-type="table"}. Their mean age was 48.5 years (range, 27--80 years). The mean pathological tumor size was 2.38 cm (range, 0.6--5.0 cm). In total, 56.4% of the SLNB findings were negative. In all patients with positive SLNs, 73.8% had only one positive SLN, 20.5% had two positive SLNs, and 5.6% had three or more positive SLNs. The false-negative rate (FNR) was 5.50% (12/218). A large tumor size (P = 0.0012), SLN positivity (P \< 0.0001), and HER-2 positivity (P = 0.0229) were independent predictors of non-SLN metastasis ([Table 2](#table2-0300060517729589){ref-type="table"}).

###### 

Comparison of characteristics of patients with breast cancer with negative versus positive non-SLNs

![](10.1177_0300060517729589-table1)

  Characteristic                 Non-SLNnegativity   Non-SLNpositivity   P
  ------------------------------ ------------------- ------------------- ----------
  Age (years)                                                            0.2850
   ≤50                           278                 51                  
   \>50                          115                 28                  
  Tumor size (cm)                                                        0.0005
   \>0.5, but ≤1                 46                  3                   
   \>1, but ≤2                   164                 19                  
   \>2, but ≤3                   120                 33                  
   \>3, but ≤4                   46                  18                  
   \>4, but ≤5                   17                  6                   
  Positive SLN                                                           \<0.0001
   0                             254                 12                  
   ≥1                            139                 67                  
  Negative SLN                                                           \<0.0001
   0                             19                  20                  
   ≥1                            374                 59                  
  Total SLN                                                              0.3642
   1                             107                 21                  
   2                             133                 21                  
   ≥3                            153                 37                  
  Multifocality                                                          0.4640
   Multifocal                    10                  3                   
   Unifocal                      383                 76                  
  Lymphovascular invasion                                                0.2479
   Present                       17                  6                   
   Absent                        376                 73                  
  Estrogen receptor status                                               1.0000
   Positive                      251                 50                  
   Negative                      142                 29                  
  Progesterone receptor status                                           0.7114
   Positive                      191                 36                  
   Negative                      202                 43                  
  HER-2 status                                                           0.0012
   Positive                      73                  30                  
   Negative                      284                 43                  
   Unknown                       36                  6                   
  Ki67 status                                                            0.1741
   Positive                      235                 56                  
   Negative                      155                 23                  
   Unknown                       3                   0                   
   Total                         393                 79                  

Data are presented as numbers of patients. SLN, sentinel lymph node

###### 

Multivariate logistic regression of the association of each variable with non-SLN metastasis

![](10.1177_0300060517729589-table2)

  Variables        Odds ratio   95% CI          P
  ---------------- ------------ --------------- ----------
  Tumor size       0.4928       1.215--2.206    0.0012
  Positive SLN     1.9903       3.230--16.577   \<0.0001
  Negative SLN     −1.4113      0.081--0.737    0.0124
  HER-2 positive   0.7808       1.114--4.277    0.0229

CI, confidence interval; SLN, sentinel lymph node

Association between number of positive/negative SLNs and non-SLN metastasis {#sec11-0300060517729589}
---------------------------------------------------------------------------

The association between the number of positive/negative SLNs and non-SLN metastasis was analyzed ([Table 3](#table3-0300060517729589){ref-type="table"}). A significant difference in non-SLN metastasis was found between the absence of positive/negative SLNs and the presence of one or more positive/negative SLNs (P\<0.0001). There was no significant difference in SLN metastasis between the presence of one positive/negative SLN and two or more positive/negative SLNs.

###### 

Association between number of positive/negative SLNs and non-SLN metastasis

![](10.1177_0300060517729589-table3)

                  Non-SLN negativity   Non-SLN positivity   P
  --------------- -------------------- -------------------- ---------------------------------------------------------------
  Positive SLNs                                             
   0              254                  12                   \<0.0001[a](#table-fn3-0300060517729589){ref-type="table-fn"}
   1              109                  46                   0.2536^b^
   2              24                   16                   0.7442^c^
   ≥3             6                    5                    
  Negative SLNs                                             
   0              19                   20                   \<0.0001[a](#table-fn3-0300060517729589){ref-type="table-fn"}
   1              144                  25                   0.8665^b^
   2              109                  17                   0.8548^c^
   ≥3             121                  17                   

^a^Compared with patients with ≥1 positive or negative SLN; ^b^Compared with patients with ≥2 positive or negative SLNs; ^c^Compared with patients with ≥3 positive or negative SLNs.

Patients who did not undergo ALND {#sec12-0300060517729589}
---------------------------------

The descriptive characteristics of the patients who did not undergo ALND (*n* = 251) are provided in [Table 4](#table4-0300060517729589){ref-type="table"}. Five of 251 patients (2.0%) were lost to follow-up. The mean age of the patients who did not undergo ALND was 51.48 years (range, 23--82 years). The mean pathological tumor size was 1.76 cm (range, 0.6--5.0 cm). Of the four patients who underwent mastectomy, the SLN of one patient was positive on frozen section, but she refused ALND because of her old age. The SLNs of the other three patients were negative on frozen section; however, although the final paraffin section was positive, these patients refused ALND after mastectomy. Two patients with micrometastases and two with isolated tumor cells underwent mastectomy without ALND. Ten patients with one positive SLN underwent breast-preserving surgery without ALND. The median patient follow-up time was 34.0 months, and the mean was 32.9 months (range, 12--74 months). No patients developed recurrence in the axilla. One patient developed recurrence in the same breast 2 years after breast-preserving surgery. Modified radical mastectomy was performed in this patient, and no lymph node metastasis was detected. In this patient, the tumor size was 2.0 cm, estrogen and progesterone receptors were negative, and HER-2/neu receptor was positive. She underwent chemotherapy and biological therapy. All other patients survived without recurrence. The recurrence-free survival rate was 99.6% (245/246).

###### 

Characteristics of patients with breast cancer who did not undergo axillary lymph node dissection

![](10.1177_0300060517729589-table4)

  Characteristic                Patients (n)
  ----------------------------- --------------
  Age (years)                   
   ≤50                          133
   \>50                         118
  Tumor size (cm)               
   \>0.5, but ≤1                76
   \>1, but ≤2                  111
   \>2, but ≤3                  49
   \>3, but ≤4                  10
   \>4, but ≤5                  5
  Positive SLNs                 
   0                            237
   1                            14
   2                            0
   ≥3                           0
  Negative SLNs                 
   0                            0
   1                            159
   2                            92
   ≥3                           0
  Surgery                       
   Breast-preserving            110
   Mastectomy                   141
  Multifocality                 
   Multifocal                   7
   Unifocal                     244
  Lymphovascular invasion       
   Present                      5
   Absent                       246
  Estrogen receptor status      
   Positive                     173
   Negative                     78
  Progestrone receptor status   
   Positive                     129
   Negative                     122
  HER-2 status                  
   Positive                     57
   Negative                     194
  Ki67 status                   
   Positive                     203
   Negative                     48
  Total                         251

SLN, sentinel lymph node

Discussion {#sec13-0300060517729589}
==========

The SLN is considered the first node that receives direct lymphatic drainage from the tumor. However, it is commonly believed that even for the most experienced surgeons, SLNB is associated with a high FNR. Pecha et al.^[@bibr9-0300060517729589]^ reported an FNR of 5% in patients with an original tumor of \<2 cm in size, 9% for tumors of 2 to 4 cm, and 13.8% for tumors of \>4 cm. Gimbergues et al.^[@bibr10-0300060517729589]^ reported an FNR of 5.7% in patients with T1-T2 cancer but 28.5% in patients with T3 cancer (P=0.045), confirming the close correlation between the FNR of SLNB and tumor volume. Thus, it is widely known that SLNB is mostly suitable for patients with T1-T2 cancer. In large tumors with an increased rate of lymphatic metastasis, the metastatic cancer cells often clog the lymphatic channels, changing the original lymphatic circulation and thus hindering the normal transfer of the imaging agent or radionuclide in the lymphatic vessels. One systematic review of 24 studies showed that the combined use of a radioisotope and blue dye had a higher identification rate of SLNs than a radioisotope alone.^[@bibr11-0300060517729589]^ Dual tracers did not significantly reduce the FNR compared with a radioisotope alone. Moreover, an overview of 69 studies of SLNB validated by concurrent ALND confirmed an SLN identification rate of 96%, with an average FNR of 7%.^[@bibr12-0300060517729589]^ In the present study, the FNR was 5.48% in patients who underwent ALND. Other researchers have reported that peripheral lymph node sampling^[@bibr13-0300060517729589]^ or atrial ALND^[@bibr14-0300060517729589]^ may further reduce the FNR of SLNB. However, more extensive surgery may lead to more unnecessary injury.

In general, SLN metastases are identified in about 30% of patients with clinically node-negative breast cancer, and half of those with positive SLNs have only SLN metastases.^[@bibr15-0300060517729589]^ Conversely, 40% of patients with MAC in the SLN have a higher probability of non-SLN metastases. Wada and Imoto^[@bibr16-0300060517729589]^ calculated the probability of non-SLN metastases using predictive factors for patients with SLN-positive breast cancer who underwent SLNB followed by ALND. They demonstrated that the tumor size, size of the largest SLN metastasis, proportion of positive SLNs among all SLNs detected, and lymphatic invasion of the tumor were independent predictive factors for non-SLN metastases. Among the patients with cT1-2 N0 breast cancer who underwent ALND, 51.3% had negative lymph node metastasis, 40.5% had one to two positive lymph nodes, and only 5.7% had three or more lymph node metastases. Hence, a higher number of SLNs obtained is not necessarily beneficial.. Three or fewer SLNs is enough for most patients. The results of the present study revealed that the presence of one negative SLN is necessary for SLNB. Moreover, there was no significant difference between the presence of one negative SLN and two or more negative SLNs. Hence, in consideration of surgical injury, obtaining two or more negative SLNs may be unnecessary. Therefore, when one or two positive SLNs are detected, one negative SLN is needed to avoid ALND. When three or more positive SLNs are detected, ALND should be carried out. For patients with negative SLNs, one to three SLNs is enough.

A large tumor size and HER-2 positivity were also identified as independent predictors of non-SLN metastasis. Therefore, when a patient has a large tumor size or HER-2 positivity, the surgeon should pay more attention to the possibility of non-SLN metastasis, and acquisition of one to two negative SLNs should be assured. Intraoperative detection of metastatic carcinoma in SLNs leads to immediate ALND, avoiding the need for a delayed second surgical procedure. Frozen section is often the preferred method for intraoperative evaluation. One meta-analysis of 47 studies involving frozen section revealed a pooled sensitivity of 73%, and the sensitivity for MAC was higher than that for micrometastases (94% vs. 40%, respectively).^[@bibr17-0300060517729589]^ Wong et al.^[@bibr18-0300060517729589]^ retrospectively reviewed 2202 SLNBs from 2174 patients with breast carcinoma at Singapore General Hospital during a 7-year period. The authors confirmed the relationship between the size of the SLN metastasis and the risk of a false-negative frozen section result. The also identified an overall FNR of 13.5%, and the FNR for detection of MAC was much lower at 3.1%. The smaller the SLN metastases, the higher the odds of a false-negative diagnosis. Rapid molecular techniques for intraoperative detection of metastatic carcinoma in SLNs are also available, but they have somewhat questionable sensitivity. However, with the wide application of the Z0011 trial, intraoperative diagnosis of SLNs and prediction of the non-SLN status have become less important.

In conclusion, research of false-negative SLNBs in patients with breast cancer has facilitated more evidence-based medicine and enabled the development of new methods with which to reduce the FNR of SLNB. With the modified indications for SLNB, the demands on technology are increasing to assure a high success rate and low FNR, which will benefit patients. Refinements of SLNBs require not only the efforts of surgeons but also the cooperation of clinicians in radiology, nuclear medicine, and pathology, making SLNB the most reliable measure in axilla-conserving treatment. Developments are moving in the direction of minimally invasive surgery. SLN-guided surgery has been widely accepted by breast surgeons. In accordance with minimal invasiveness, SLNB should avoid unnecessary injury. Assurance of the appropriate number of SLNs is important.

Abbreviations {#sec14-0300060517729589}
=============

SLN=sentinel lymph node

ALND=axillary lymph node dissection

SLNB=sentinel lymph node biopsy

FNR=false-negative rate

MAC=macrometastases
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